The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.14251
Abstract: Hereditary angioedema (HAE) due to C1‐inhibitor deficiency (C1‐INH‐HAE) is a rare, potentially fatal, bradykinin‐mediated disease. Icatibant is a bradykinin B2 receptor antagonist originally approved in 2008 in the European Union and 2011 in the United… read more here.
Keywords: experience hereditary; hereditary angioedema; outcome survey; icatibant outcome ... See more keywords